Caribou Biosciences (CRBU) vs Champions Oncology (CSBR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Champions Oncology (CSBR) has outperformed Caribou Biosciences (CRBU) over the past year, losing 25.4% versus a loss of 74.6%. Over five years, CSBR leads with a -51.6% price change compared with -97.0% for CRBU. Champions Oncology is the larger company by market cap ($67.9 million vs $66.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | CSBR |
|---|---|---|
| Share price | $0.6174 | $4.88 |
| Market cap | $66.19M | $67.92M |
| 1-day change | -45.60% | -2.59% |
| YTD return | -61.17% | -29.38% |
| 1-year return | -74.59% | -25.38% |
| 5-year return | -97.04% | -51.59% |
| Forward P/E | — | 48.80 |
| EPS (TTM) | $-1.08 | $-0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $8.31 |
| 52-week low | $0.546 | $4.59 |
| Distance from 52-week high | -82.53% | -41.28% |
| Average volume | 1.31M | 11.25K |
| Shares outstanding | 107.21M | 13.92M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed CRBU by 49.2 percentage points over the past year.
CRBU vs CSBR FAQ
Which is bigger, Caribou Biosciences or Champions Oncology?
Champions Oncology (CSBR) is larger, with a market capitalization of $67.92M compared with $66.19M for Caribou Biosciences (CRBU).
Which stock has performed better over the past year, CRBU or CSBR?
CSBR returned -25.38% over the past 12 months, compared with -74.59% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Caribou Biosciences and Champions Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.